

# NEW HORIZONS



Boosting empowerment and breaking the bonds of homophobia, racism, and stigma in same gender-loving men in Baltimore City NETWORKING - HIV 411 - SOCIAL EVENTS - ART CREATION PROJECT

AIDS Action Baltimore, 410-837-5573 / NewHorizonBaltimore410@gmail.com
HIV Prevention Advocacy for SGL Men's Health supported by
ViiV Healthcare's ACCELERATE! Program

# CROI PrEP 2018 UPDATE Lynda Dee

June 27, 2018

- Please Sign the Sign-In Sheet
- Please Complete an Evaluation
- AAB: 410-837-AIDS (410) 837-2437
- FB: New Horizons or aidsactionbaltimore.org

- HIV TRANSMISSION RATE STATISTICS
- CDC PrEP USE REPORT FOR Q2 2017
- CDC PrEP STATS FOR THOSE NEEDING PrEP
- Prep data from atlanta, chicago, nyc and cdc demo project: Sf, dc and miami
- NEW Prep Drugs, Taf+ftc, IM La Cabotegravir and Weekly Oral MK-8591 IN Monkeys
- NEW CASE OF TDF+FTC RESISTANCE

- CDC HIV Transmission Statistics
  - •1 in 49 in Maryland
  - 1 in 20 in Black Men in the US
  - 1 in 2 in Black MSM in the US
  - All MSM, especially black MSM must remain a high priority for PrEP delivery

- CDC National Quarterly PrEP Use Estimate
- 61,000 prescriptions in Q2 of 2017
- Much lower than the previous estimate of 120,000
- Some decrease expected as discontinuations occur
- Only 5% of 1.2mil for whom PrEP is indicated are actually receiving prescriptions
- PrEP needs to be scaled up in all populations

- CDC National Quarterly PrEP Use Estimate
- PrEP only 9,150 women were using PrEP
- PrEP use in the South is half the next lowest region
- PrEP-to-need ration is lower among youth
- States in the highest poverty quartile, % uninsured and % of African-Americans (south & midwest) had lower PrEP use

- PrEP is indicated for 1,145,00 (9-2015/8-2016)
- 814,000 MSM, 258,000 heteros, 73,000 IVDUs
- 43.7% African-Americans need PrEP, use = 1%
- 24.7% Latinos need PrEP, use = 3%
- 26.5 white need PrEP, use = 14%
- Only 8% for all people for whom PrEP was indicated

- Fulton County Board of Health (Atlanta)
  - Higher PrEP uptake in white MSM and lower continued use in black MSM
  - PrEP implementation in this county health department setting reached key populations
  - Overall uptake and persistence were suboptimal
  - Recommendations: intensify outreach, education and streamline process

- Northwestern University (Chicago)
  - PrEP use in YMSM (16-29 male at birth) increased from 6.6% to 17.2%, but 33% discontinued PrEP
  - Primary reasons:
    - Problems getting appointments (21.5%)
    - Insurance coverage or loss (20%)

- PrEP Use in Newly Diagnosed in NYC Clinics
  - NYC Sexual Health Clinics were excellent PrEP implementation settings
  - Disproportionately low PrEP use in black heterosexuals and females may suggest disparities in awareness and accessibility
  - High risk sexual behaviors and STIs were common, indicating the need for stronger condom use messaging and regular follow-up

- MSM and Trans Women Retained in US PrEP Demo Project in Miami, San Francisco and DC
- 366/554 (66.1%) of all participants retained
- 127/554 (22.9%) had intermittent retention
- 61/554 (11%) lost to follow-up in first 12 wks
- Black MSM and younger adults = intermittent and ELTF (early loss to follow-up/first 12 wks)
- Early interventions may promote continuation

- FTC/TAF Prevents Vaginal SHIV in Monkeys
- Oral FTC/TAF 24h before and 2h after vaginal exposure prevented SHIV similar to FTC/TDF
- Only one infection seen from low drug levels
- Expands results of FTC/TAF in rectal SHIV
- Findings support FTC/TAF for PrEP against vaginal HIV infection in women as well as men

- Long Acting Cabotegravir and Penile SHIV
- Validated the penile repeat exposure SHIV transmission model with oral FTC/TDF
- LA CAB protects monkeys against penile infection
- Penile concentrations similar to rectum
- High efficacy supports trials for LA CAB for penile HIV (accounts for half the HIV infections)

- Oral MK-8591 Prevents Rectal SHIV
- Efficacy of different doses of oral MK-8591
- Suggests effective weekly oral dosing
- 92% protection rate in monkeys challenged rectally weekly with SHIV
- No safety issues were noted with oral MK-8591
- Suggests an oral weekly dose of MK-8591 that will be effective in humans

- HIV Transmission While on PrEP
  - Patient given an 11 refill Rx, was told to return for follow-up visits, did not return as directed
  - Acquired HIV with a resistance mutation
  - Kept using FTC/TDF after being infected which probably caused two other resistance mutations
  - Proper prescribing and follow-up would have allowed for quicker identification of HIV and may have prevented additional resistance

- Please Sign the Sign-In Sheet
- Please Complete an Evaluation
- AAB: 410-837-AIDS (410) 837-2437
- FB: New Horizons or aidsactionbaltimore.org

- THANK YOU FOR ATTENDING
- Jeffrey Grabelle, Falina Chanel, Ali
   Moody and Jay Mangum
- NATAP.org
- Gilead Sciences
- ViiV Healthcare